# Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer

> **NCT03654716** · PHASE1 · COMPLETED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 21 (actual)

## Conditions studied

- Leukemia
- Brain Tumor
- Solid Tumor
- Lymphoma

## Interventions

- **DRUG:** ALRN-6924
- **DRUG:** Cytarabine

## Key facts

- **NCT ID:** NCT03654716
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-01
- **Primary completion:** 2023-07-17
- **Final completion:** 2023-07-17
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2025-02-14

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03654716

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03654716, "Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT03654716. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*